Cargando…
Patient‐Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs
Regulatory decisions may be enhanced by incorporating patient preferences for drug benefit and harms. This study demonstrates a method of weighting clinical evidence by patients’ benefit–risk preferences. Preference weights, derived from discrete choice experiments, were applied to clinical trial da...
Autores principales: | Holmes, Emily A.F., Plumpton, Catrin, Baker, Gus A., Jacoby, Ann, Ring, Adele, Williamson, Paula, Marson, Anthony, Hughes, Dyfrig A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491963/ https://www.ncbi.nlm.nih.gov/pubmed/30204252 http://dx.doi.org/10.1002/cpt.1231 |
Ejemplares similares
-
Using discrete choice experiments to define patient preferences for outcomes in trials
por: Fargher, Emily, et al.
Publicado: (2013) -
Renal transplant patients’ preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment
por: Hagemi, Anke, et al.
Publicado: (2017) -
Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II)
por: Balabanova, Silviya, et al.
Publicado: (2020) -
Patient Preference for Antiepileptic Drugs Treatment in China: Evidence From the Discrete Choice Experiment
por: Hua, Yingjie, et al.
Publicado: (2020) -
Treatment outcome after failure of a first antiepileptic drug
por: Bonnett, Laura J., et al.
Publicado: (2014)